Last updated: February 26, 2026
What is the excipient profile for ALLERGY RELIEF-D24 HOUR?
ALLERGY RELIEF-D24 HOUR is an extended-release antihistamine formulation typically encapsulated or compressible into tablets. Its formulation focuses on sustaining drug release over 24 hours, requiring excipients that support controlled-release mechanisms.
Key excipients include:
- Hydrophilic polymers: Hydroxypropyl methylcellulose (HPMC), cellulose derivatives
- Breakable matrix agents: Polyethylene oxide (PEO)
- Binders: Microcrystalline cellulose (MCC)
- Disintegrants: Cross-linked polyvinylpyrrolidone (Crospovidone)
- Lubricants: Magnesium stearate
- Fillers/diluents: Lactose, dibasic calcium phosphate
These excipients facilitate sustained drug release, improve stability, and ensure manufacturing consistency. The choice hinges on compatibility with the active drug and the desired pharmacokinetic profile.
How do excipients influence formulation performance?
Excipients underpin critical attributes:
- Controlled-release efficiency: Hydrophilic polymers form gel barriers that modulate drug diffusion. Their molecular weight and cross-linking degree alter release rates.
- Stability: Proper binders and fillers protect active ingredients from degradation.
- Manufacturing: Lubricants reduce tablet ejection friction, and fillers adjust tablet size and weight.
- Patient acceptability: Disintegrants promote quick disintegration, ensuring timely onset, while flavoring and sweeteners may improve palatability.
Achieving consistent performance requires precise excipient proportions, manufacturing controls, and thorough stability testing.
What are current market trends and opportunities?
The extended-release antihistamine market is expanding, driven by consumer demand for convenience and better compliance. Key trends include:
- Innovative release mechanisms: Multi-layered tablets, osmotic systems, and matrix modifications enhance release control.
- Preference for excipient safety profiles: Regulatory agencies favor excipients with well-documented safety data.
- Combination formulations: Pairing antihistamines with decongestants or corticosteroids broadens consumer appeal.
Commercial opportunities arise from encapsulation of existing formulations into new dosage forms, developing improved controlled-release matrices, or leveraging novel excipients with better biocompatibility.
What are the patent and regulatory considerations?
Patent protection often covers active compounds, with excipient choices protected via formulation patents. Regulatory pathways favor excipients with established safety profiles, such as those listed in the INCI or USP/NF monographs.
Any novel excipient or innovative release technology must undergo safety evaluation and may require pre-market approval (PMR) or investigational new drug (IND) submissions.
How to formulate a competitive excipient strategy?
A robust approach involves:
- Prioritizing excipients with GRAS (Generally Recognized as Safe) status
- Ensuring compatibility with API and release profile requirements
- Utilizing excipients that facilitate manufacturing scalability
- Incorporating optional functionalities like taste masking or stability enhancers
- Ensuring patentability through novel excipient combinations or delivery mechanisms
What are the commercial considerations for suppliers?
Excipients suppliers can capitalize by:
- Developing specialized controlled-release polymers
- Offering excipients optimized for allergen formulations
- Providing excipients with proven stability and regulatory acceptance
- Establishing partnerships with pharmaceutical manufacturers for integrated supply
Market entry depends on alignment with pharmaceutical client needs, regulatory compliance, and competitive pricing.
Key Opportunities
- Developing proprietary polymer blends for improved release control
- Formulating excipient systems that enhance stability in tropical climates
- Creating combinations that reduce manufacturing costs
- Innovating with allergen-specific excipients to address niche markets
- Packaging excipient solutions compatible with scalable manufacturing equipment
Key Takeaways
- The excipient matrix for ALLERGY RELIEF-D24 HOUR hinges on hydrophilic polymers and disintegrants that support controlled release.
- Innovation in excipient technology offers opportunities for differentiation, patenting, and meeting regulatory standards.
- Market growth is driven by demand for convenient, long-acting allergy treatments and combination therapies.
- Suppliers focusing on safety, scalability, and regulatory compliance can command competitive advantages.
- Formulation strategies should align excipient choices with pharmacokinetic goals and manufacturing capabilities.
FAQs
-
What excipients are most critical for extended-release allergy medications?
Hydrophilic polymers like HPMC and PEO are critical for controlling drug release, along with binders and disintegrants that ensure proper tablet performance.
-
How can excipient innovation impact patent protection?
Novel excipient combinations or delivery mechanisms can lead to new patents, providing exclusivity for formulation advances.
-
What are regulatory considerations in selecting excipients?
Excipients must be recognized as safe (GRAS) or approved by regulatory agencies like the FDA or EMA; new excipients require safety data and approval.
-
Which strategies can reduce manufacturing costs?
Simplifying excipient systems, using widely available approved excipients, and designing formulations compatible with high-speed manufacturing reduce costs.
-
What trends are shaping future excipient development?
Focus areas include biocompatibility, stability in extreme climates, and formulations supporting multi-drug or personalised therapies.
References:
[1] U.S. Food and Drug Administration. (2021). Excipients in Drug Products. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/excipients-approved
[2] European Medicines Agency. (2022). Guideline on excipients in the Label and Package leaflet of medicinal products for human use. EMA/CHMP/QWP/545525/2020
[3] Lee, V. (2019). Controlled Release Formulation Design. Pharmaceutical Technology.
